MAb 9F4 provides heterologous protection against multiple influenza A H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope. The present invention relates to isolated mouse-human chimeric (xi) IgG1-9F4 and IgA1-9F4 MAb which retain high degrees of binding and neutralizing activity against influenza H5N1. The invention also relates to methods of production, kits and uses of the chimeric antibodies in the treatment of influenza A subtype H5N1 disease.
展开▼
机译:MAb 9F4通过与新型表位结合,提供针对多种A A H5N1流感病毒进化枝病毒的异源保护,其中包括最近指定的一个子序列2.3.4。本发明涉及分离的小鼠-人嵌合(xi)IgG1-9F4和IgA1-9F4MAb,它们保留了针对流感H5N1的高度结合和中和活性。本发明还涉及嵌合抗体在治疗甲型流感H5N1亚型疾病中的生产方法,试剂盒和用途。
展开▼